Meeting Coverage > > ASH: Hematology– Personalized, time-limited routine of venetoclax plus ibrutinib enhances survival versus FCR
by Ian Ingram, Managing Editor, MedPage Today December 10, 2023
SAN DIEGO– A time-limited, targeted mix substantially enhanced survival compared to chemoimmunotherapy in healthy persistent lymphocytic leukemia (CLL) clients who satisfied requirements for beginning treatment, findings from the randomized FLAIR trial showed.
At 3 years, progression-free survival (PFS) rates reached 97% for clients randomized to venetoclax (Venclexta) plus ibrutinib (Imbruvica), as compared to 77% for those appointed to the basic chemoimmunotherapy program of fludarabine, cyclophosphamide, and rituximab (FCR), reported Peter Hillmen, MBChB, PhD, of St. James’s University Hospital in Leeds, England.
The venetoclax-ibrutinib routine likewise considerably enhanced total survival (OS)– with deaths taking place in 2% of clients treated with the targeted mix at this time point versus 7% of those appointed to chemoimmunotherapy– better actions, and was connected with half as lots of secondary cancers, according to findings detailed throughout a press instruction here at the American Society of Hematology yearly conference.
In a declaration, Hillmen stated the time-limited method represents “a brand-new gold requirement for formerly unattended CLL.”
This research study “unquestionably reveals the supremacy of targeted treatment over standard cytotoxic chemotherapy,” stated press instruction mediator Mikkael Sekeres,